Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Ticker
$BIIB
Sector
Primary listing
Employees
7,605
Headquarters
Website
Biogen Metrics
BasicAdvanced
$21B
13.86
$10.45
0.11
-
Price and volume
Market cap
$21B
Beta
0.11
52-week high
$200.11
52-week low
$110.04
Average daily volume
1.5M
Financial strength
Current ratio
2.503
Quick ratio
1.521
Long term debt to equity
37.397
Total debt to equity
37.397
Interest coverage (TTM)
9.82%
Profitability
EBITDA (TTM)
3,222.4
Gross margin (TTM)
75.58%
Net profit margin (TTM)
15.31%
Operating margin (TTM)
24.79%
Effective tax rate (TTM)
14.86%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
5.62%
Return on equity (TTM)
9.13%
Valuation
Price to earnings (TTM)
13.858
Price to revenue (TTM)
2.116
Price to book
1.2
Price to tangible book (TTM)
12.69
Price to free cash flow (TTM)
11.547
Free cash flow yield (TTM)
8.66%
Free cash flow per share (TTM)
12.546
Growth
Revenue change (TTM)
3.36%
Earnings per share change (TTM)
31.67%
3-year revenue growth (CAGR)
-2.04%
10-year revenue growth (CAGR)
-0.30%
3-year earnings per share growth (CAGR)
-9.19%
10-year earnings per share growth (CAGR)
-3.39%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Bulls say / Bears say
In July 2025, Biogen announced a $2 billion investment to expand its North Carolina manufacturing plants—adding fill-finish, automation, and AI systems—to boost domestic production ahead of possible U.S. drug tariffs.
In August 2025, the FDA approved an at-home, weekly injectable version of Leqembi—called Leqembi IQLIK—making treatment easier to administer and expected to increase patient adoption.
In April 2025, the European Commission approved Leqembi for early-stage Alzheimer’s, making it the first EU-approved drug targeting the root cause of the disease, with analysts projecting peak sales of over $900 million in the 2030s.
In Q1 2025, Biogen’s multiple sclerosis drug sales fell by 11%, putting more pressure on its main business as competition increases.
The company booked a $165 million licensing charge in Q1 2025 from a deal with Stoke Therapeutics, leading it to lower its full-year EPS guidance to $14.50–$15.50.
Leqembi brought in just $52 million in U.S. sales for Q1 2025, showing sluggish uptake due to ongoing concerns about pricing, effectiveness, and required monitoring for side effects.
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $21B as of September 18, 2025.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 13.86 as of September 18, 2025.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.